10 mg lyophilised · blend - CJC-1295 (no DAC) + Ipamorelin
$110.00 CAD
CJC-1295 + Ipamorelin pairs two peptides - CJC-1295 (no DAC) and Ipamorelin - that prompt the body's own release of growth hormone. The combination is studied in endocrine research on how the two work together on the growth-hormone axis.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsCJC-1295 + Ipamorelin combines two peptides that both prompt the body to release its own growth hormone, through different doorways. CJC-1295 (no DAC) is an analogue (a close synthetic copy) of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective agonist (a clean “activator”) of the GH-secretagogue receptor, also called the ghrelin receptor.
Each component has its own human pharmacology literature. CJC-1295 produced sustained, dose-dependent rises in growth hormone and IGF-1 (a downstream growth-signalling hormone) in healthy adults; Ipamorelin was characterised as the first selective GH secretagogue, releasing GH with little effect on other hormones such as cortisol and prolactin. The combination is studied for how the two pathways act together to produce pulse-like GH release.
The two act on complementary receptors - the GHRH receptor (CJC-1295) and the ghrelin/GH-secretagogue receptor (Ipamorelin) - which in models amplifies natural, pulsatile GH secretion more than either alone.
Neither component is an approved medicine; both are research compounds. Supplied strictly as research material - not for human consumption.
A single vial containing a 10 mg combined blend of CJC-1295 (no DAC) and Ipamorelin as a lyophilised powder.
